Clinical characteristics and prognostic implications in patients with HER2-low breast cancer undergoing neoadjuvant chemotherapy: a retrospective cohort study

被引：0
|
作者：
Zheng, Ang [1 ]
He, Junlin [2 ]
Li, Muyao [1 ]
Yao, Fan [1 ]
Jin, Feng [1 ]
Chen, Bo [1 ]
Wang, Xin [2 ]
机构：
[1] China Med Univ, Hosp 1, Shenyang, Peoples R China
[2] China Med Univ, Shenyang, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2025年 / 55卷
关键词：
HER2; Low; Breast Cancer;
D O I：
10.1016/j.lanwpc.2024.101378
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [22] Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer
    Qiao, Weiqiang
    Guo, Wanying
    Liu, Qipeng
    Guo, Xiao
    Deng, Miao
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 64
  • [23] HELENA: Study of HER2-low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    Cherifi, F.
    Da Silva, A.
    Johnson, A. C.
    Fournier, C. Blanc
    Broyelle, A.
    Abramovici, O.
    Morel, A.
    Bertho, M.
    Hrab, I.
    Allouache, D.
    Djezzer, C. Segura
    Levy, C.
    Boscher, C.
    Villemin, M.
    Rottier, P.
    Lequesne, J.
    Emile, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S172 - S172
  • [24] HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications
    Tarantino, Paolo
    Niman, Samuel M.
    Erick, Timothy K.
    Priedigkeit, Nolan
    Harrison, Beth T.
    Giordano, Antonio
    Nakhlis, Faina
    Bellon, Jennifer R.
    Parker, Tonia
    Strauss, Sarah
    Jin, Qingchun
    King, Tari A.
    Overmoyer, Beth A.
    Curigliano, Giuseppe
    Regan, Meredith M.
    Tolaney, Sara M.
    Lynce, Filipa
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : 277 - 286
  • [25] Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Lee, Young Joo
    Yoo, Tae-Kyung
    Lee, Sae Byul
    Chung, Il Yong
    Kim, Hee Jeong
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Ahn, Sei Hyun
    Jeong, Hyehyun
    Jung, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Jisun
    JOURNAL OF BREAST CANCER, 2025, 28 (01) : 11 - 22
  • [26] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [27] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [28] Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
    Tang, Lingfeng
    Jiang, Linshan
    Shu, Xiujie
    Jin, Yudi
    Yu, Haochen
    Liu, Shengchun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [29] Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness
    Zhao, Wei
    Zhang, Mingxiang
    Zhu, Bohui
    Pan, Yueyin
    Sun, Yiyuan
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2025, 34 (03) : 241 - 254
  • [30] Gene Mutation Spectrum in Luminal/HER2-low Early Breast Cancer after Neoadjuvant Chemotherapy: A Prospective, Multicenter Cohort Study
    Yang, Y.
    Chen, J.
    Zhu, Y.
    Gong, C.
    BREAST, 2025, 80
12345